Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2023

Poster session 06

2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant

Date

21 Oct 2023

Session

Poster session 06

Topics

Supportive Care and Symptom Management

Tumour Site

Ovarian Cancer

Presenters

Carmine Valenza

Citation

Annals of Oncology (2023) 34 (suppl_2): S1080-S1134. 10.1016/S0923-7534(23)01268-1

Authors

C. Valenza1, E. Nicolo1, M. Mongillo2, D. Trapani1, F. Gigli3, L. Boldrini1, L. Boscolo Bielo1, G. Castellano1, L. Guidi1, J. Katrini1, G. Pellizzari1, J. Villa4, I.T. Lorenzetti5, S. Derio5, M.T. La Presa5, G. Parma5, G. Curigliano1, N. Colombo5

Author affiliations

  • 1 Department Of Oncology And Hemato-oncology, University Of Milan, Milan, European Institute of Oncology IRCCS, Division of New Drugs and Early Drug Development for Innovative Therapies., 20141 - Milan/IT
  • 2 Aou Integrata Borgo Roma Verona,dipartimento Oncologia, European Institute of Oncology IRCCS, 37134 - Verona/IT
  • 3 Division Of Haematology Oncology, European Institute of Oncology IRCCS, Division of New Drugs and Early Drug Development for Innovative Therapies., 20141 - Milan/IT
  • 4 Division Of Pharmacy, European Institute of Oncology, IRCCS, Milan, Italy, 20141 - Milan/IT
  • 5 Division Of Gynecologic Oncology, European Institute of Oncology IRCCS, 20141 - Milan/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Abstract 2041P

Background

Pts with a germline BRCA pathogenic variant (gBRCA-PVs) and aHGOC report increased HAEs with platinum salts (PSs), for a possible more susceptibility of the hemopoietic stem cells to to DNA damaging agents. Also, MDS/AML cells seem to be enriched in gBRCA-PVs. The risk of PARPi-related HAEs and MDS/AML according to gBRCA-PV status in currently unknown.

Methods

We conducted a retrospective single-centre study to evaluate HAEs³G2 and MDS/AML in pts with aHGOC receving PARPi, according to the presence of a gBRCA-PV. Pts included had received a PARPi as maintenance therapy for ≥8 weeks, in any line of therapy, from Feb 2017 to Dec 2022, and had known gBRCA status. HAEs were identified by electronic medical record review, classified per CTCAE v5.0 and expressed as proportion of patients with at least one event. Onset of AML/MDS was tracked also beyond the end of treatment with PARPi (possible later occurrence), up to the last follow-up. Correlative analyses were performed (significance at p-value<0.05).

Results

166 pts were included: 95 (57%) had a gBRCA-PV. Patient characteristics, HAEs and MDS/AML are reported in in the table. At univariate analysis, gBRCA-PV status was not associated with PARPi-related HAEs, but was correlated with appearance of MDSs (9/95 vs. 1/71; p=0.04), which led to most of PARPi-discontinuations due to HAE/MDS/AML (12/95 vs. 2/71; p=0.02); 3/10 MDSs occurred during PARPi. Table: 2041P

Patient characteristics and HAEs

gBRCA-PV+ N=95 gBRCA-PV- N=71 p
Age at baseline, mean (SD) 56.6 (8.9) 60.1 (9.9) .01
Line of PARPi, median (IQR) 2 (1-3) 2 (1-3) .79
Type of PARPi <.001
Olaparib - % 61% 19%
Niraparib - % 21% 29%
Rucaparib - % 9% 1%
Previous chemotherapy for other cancers - % 10 4 .79
N° of cycles of PARPi, median (IQR) 11 (8-24) 13 (6-22) .34
HAEs - % of pts with at least one event
Any HAE* ³G2 47% 28% .67
A ³G2 33% 16% .55
N ³G2 20% 14% .37
T ³G2 10% 6% .83
MDS/AML 10% 2% .16
MDS 9% 1% .04
AML 2% 1% 1.00
Hospitalization for HAE 3% 2% 1.00
Dose reduction for HAE 25% 16% .61
Dose delay for HAE 30% 18% .70
Discontinuation for HAE or MDS/AML 11% 1% .02

*A (anemia), N (neutropenia) or T (thrombocytopenia).

Conclusions

Unlike PSs, gBRCA-PVs are not associated with PARPi-related HAEs in pts with aHGOC. MDSs are more frequent in gBRCA-PV carriers. The interaction between gBRCA-PV, MDSs and PARPi warrants further investigation.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.